Clinical Trial Detail

NCT ID NCT02753686
Title Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Exemestane

Fulvestrant

Letrozole

Anastrozole

Exemestane + Everolimus

Age Groups: adult

Additional content available in CKB BOOST